The prognostic differences and the effect of postmastectomy radiotherapy between post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 breast cancer
Abstract Background The prognosis and the value of postmastectomy radiotherapy (PMRT) between post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 breast cancer (BC) remain controversial. We aimed to evaluate the prognostic differences and the effect of PMRT between the two patient subsets. Methods Pati...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-04-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5610 |
| _version_ | 1797838383377022976 |
|---|---|
| author | Tian Yang Xiaorong Zhong Jun Wang Zhongzheng Xiang Yuanyuan Zeng Siting Yu Zelei Dai Ningyue Xu Ting Luo Lei Liu |
| author_facet | Tian Yang Xiaorong Zhong Jun Wang Zhongzheng Xiang Yuanyuan Zeng Siting Yu Zelei Dai Ningyue Xu Ting Luo Lei Liu |
| author_sort | Tian Yang |
| collection | DOAJ |
| description | Abstract Background The prognosis and the value of postmastectomy radiotherapy (PMRT) between post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 breast cancer (BC) remain controversial. We aimed to evaluate the prognostic differences and the effect of PMRT between the two patient subsets. Methods Patients diagnosed with pT1‐2N1M0 BC were identified between 2010 and 2018. The study endpoints were overall survival (OS), breast cancer‐specific survival (BCSS), locoregional recurrence‐free survival (LRFS), distant metastasis‐free survival (DMFS) and disease‐free survival (DFS). The chi‐square test, Kaplan–Meier method and Cox regression analysis were used for data analysis. Results Total number of 2103 pT1‐2N1M0 BC patients were included in the study, including 270 post‐chemotherapy (97 without PMRT, 173 with PMRT) and 1833 de novo cases (993 without PMRT, 840 with PMRT). No significant differences were found between post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 BC patients in 5‐year OS (p = 0.068), BCSS (p = 0.054), LRFS (p = 0.241), DMFS (p = 0.104) or DFS (p = 0.08). PMRT did not improve any survival outcome in patients receiving neoadjuvant chemotherapy; however, the PMRT group had a better 5‐year BCSS (97.0% vs. 95.8%, p = 0.033) in de novo pT1‐2N1 BC. Cox multivariate analysis demonstrated that PMRT was a significant independent predictor of BCSS (HR 0.628; 95% CI, 0.403–0.978; p = 0.04) in de novo pT1‐2N1 patients. Conclusions There seemed no survival difference in post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 BC patients with contemporary systemic therapy. In addition, PMRT might be exempted in patients with post‐chemotherapy ypT1‐2ypN1 BC, while not in patients with de novo pT1‐2N1 BC. |
| first_indexed | 2024-04-09T15:40:58Z |
| format | Article |
| id | doaj.art-912c9b51e7e8434da1b926c9a7aa09c0 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-09T15:40:58Z |
| publishDate | 2023-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-912c9b51e7e8434da1b926c9a7aa09c02023-04-27T10:12:43ZengWileyCancer Medicine2045-76342023-04-011278112812110.1002/cam4.5610The prognostic differences and the effect of postmastectomy radiotherapy between post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 breast cancerTian Yang0Xiaorong Zhong1Jun Wang2Zhongzheng Xiang3Yuanyuan Zeng4Siting Yu5Zelei Dai6Ningyue Xu7Ting Luo8Lei Liu9Department of Head and Neck Oncology, Cancer Center, and State Key Laboratory of Biotherapy, West China Hospital Sichuan University Chengdu ChinaBreast Disease Center, Cancer Center, West China Hospital Sichuan University Chengdu ChinaDepartment of Head and Neck Oncology, Cancer Center, and State Key Laboratory of Biotherapy, West China Hospital Sichuan University Chengdu ChinaDepartment of Head and Neck Oncology, Cancer Center, and State Key Laboratory of Biotherapy, West China Hospital Sichuan University Chengdu ChinaDepartment of Head and Neck Oncology, Cancer Center, and State Key Laboratory of Biotherapy, West China Hospital Sichuan University Chengdu ChinaDepartment of Head and Neck Oncology, Cancer Center, and State Key Laboratory of Biotherapy, West China Hospital Sichuan University Chengdu ChinaDepartment of Head and Neck Oncology, Cancer Center, and State Key Laboratory of Biotherapy, West China Hospital Sichuan University Chengdu ChinaDepartment of Head and Neck Oncology, Cancer Center, and State Key Laboratory of Biotherapy, West China Hospital Sichuan University Chengdu ChinaBreast Disease Center, Cancer Center, West China Hospital Sichuan University Chengdu ChinaDepartment of Head and Neck Oncology, Cancer Center, and State Key Laboratory of Biotherapy, West China Hospital Sichuan University Chengdu ChinaAbstract Background The prognosis and the value of postmastectomy radiotherapy (PMRT) between post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 breast cancer (BC) remain controversial. We aimed to evaluate the prognostic differences and the effect of PMRT between the two patient subsets. Methods Patients diagnosed with pT1‐2N1M0 BC were identified between 2010 and 2018. The study endpoints were overall survival (OS), breast cancer‐specific survival (BCSS), locoregional recurrence‐free survival (LRFS), distant metastasis‐free survival (DMFS) and disease‐free survival (DFS). The chi‐square test, Kaplan–Meier method and Cox regression analysis were used for data analysis. Results Total number of 2103 pT1‐2N1M0 BC patients were included in the study, including 270 post‐chemotherapy (97 without PMRT, 173 with PMRT) and 1833 de novo cases (993 without PMRT, 840 with PMRT). No significant differences were found between post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 BC patients in 5‐year OS (p = 0.068), BCSS (p = 0.054), LRFS (p = 0.241), DMFS (p = 0.104) or DFS (p = 0.08). PMRT did not improve any survival outcome in patients receiving neoadjuvant chemotherapy; however, the PMRT group had a better 5‐year BCSS (97.0% vs. 95.8%, p = 0.033) in de novo pT1‐2N1 BC. Cox multivariate analysis demonstrated that PMRT was a significant independent predictor of BCSS (HR 0.628; 95% CI, 0.403–0.978; p = 0.04) in de novo pT1‐2N1 patients. Conclusions There seemed no survival difference in post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 BC patients with contemporary systemic therapy. In addition, PMRT might be exempted in patients with post‐chemotherapy ypT1‐2ypN1 BC, while not in patients with de novo pT1‐2N1 BC.https://doi.org/10.1002/cam4.5610breast cancerde novo pT1‐2N1neoadjuvant chemotherapypost‐chemotherapy ypT1‐2ypN1postmastectomy radiotherapyprognosis |
| spellingShingle | Tian Yang Xiaorong Zhong Jun Wang Zhongzheng Xiang Yuanyuan Zeng Siting Yu Zelei Dai Ningyue Xu Ting Luo Lei Liu The prognostic differences and the effect of postmastectomy radiotherapy between post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 breast cancer Cancer Medicine breast cancer de novo pT1‐2N1 neoadjuvant chemotherapy post‐chemotherapy ypT1‐2ypN1 postmastectomy radiotherapy prognosis |
| title | The prognostic differences and the effect of postmastectomy radiotherapy between post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 breast cancer |
| title_full | The prognostic differences and the effect of postmastectomy radiotherapy between post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 breast cancer |
| title_fullStr | The prognostic differences and the effect of postmastectomy radiotherapy between post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 breast cancer |
| title_full_unstemmed | The prognostic differences and the effect of postmastectomy radiotherapy between post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 breast cancer |
| title_short | The prognostic differences and the effect of postmastectomy radiotherapy between post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 breast cancer |
| title_sort | prognostic differences and the effect of postmastectomy radiotherapy between post chemotherapy ypt1 2ypn1 and de novo pt1 2n1 breast cancer |
| topic | breast cancer de novo pT1‐2N1 neoadjuvant chemotherapy post‐chemotherapy ypT1‐2ypN1 postmastectomy radiotherapy prognosis |
| url | https://doi.org/10.1002/cam4.5610 |
| work_keys_str_mv | AT tianyang theprognosticdifferencesandtheeffectofpostmastectomyradiotherapybetweenpostchemotherapyypt12ypn1anddenovopt12n1breastcancer AT xiaorongzhong theprognosticdifferencesandtheeffectofpostmastectomyradiotherapybetweenpostchemotherapyypt12ypn1anddenovopt12n1breastcancer AT junwang theprognosticdifferencesandtheeffectofpostmastectomyradiotherapybetweenpostchemotherapyypt12ypn1anddenovopt12n1breastcancer AT zhongzhengxiang theprognosticdifferencesandtheeffectofpostmastectomyradiotherapybetweenpostchemotherapyypt12ypn1anddenovopt12n1breastcancer AT yuanyuanzeng theprognosticdifferencesandtheeffectofpostmastectomyradiotherapybetweenpostchemotherapyypt12ypn1anddenovopt12n1breastcancer AT sitingyu theprognosticdifferencesandtheeffectofpostmastectomyradiotherapybetweenpostchemotherapyypt12ypn1anddenovopt12n1breastcancer AT zeleidai theprognosticdifferencesandtheeffectofpostmastectomyradiotherapybetweenpostchemotherapyypt12ypn1anddenovopt12n1breastcancer AT ningyuexu theprognosticdifferencesandtheeffectofpostmastectomyradiotherapybetweenpostchemotherapyypt12ypn1anddenovopt12n1breastcancer AT tingluo theprognosticdifferencesandtheeffectofpostmastectomyradiotherapybetweenpostchemotherapyypt12ypn1anddenovopt12n1breastcancer AT leiliu theprognosticdifferencesandtheeffectofpostmastectomyradiotherapybetweenpostchemotherapyypt12ypn1anddenovopt12n1breastcancer AT tianyang prognosticdifferencesandtheeffectofpostmastectomyradiotherapybetweenpostchemotherapyypt12ypn1anddenovopt12n1breastcancer AT xiaorongzhong prognosticdifferencesandtheeffectofpostmastectomyradiotherapybetweenpostchemotherapyypt12ypn1anddenovopt12n1breastcancer AT junwang prognosticdifferencesandtheeffectofpostmastectomyradiotherapybetweenpostchemotherapyypt12ypn1anddenovopt12n1breastcancer AT zhongzhengxiang prognosticdifferencesandtheeffectofpostmastectomyradiotherapybetweenpostchemotherapyypt12ypn1anddenovopt12n1breastcancer AT yuanyuanzeng prognosticdifferencesandtheeffectofpostmastectomyradiotherapybetweenpostchemotherapyypt12ypn1anddenovopt12n1breastcancer AT sitingyu prognosticdifferencesandtheeffectofpostmastectomyradiotherapybetweenpostchemotherapyypt12ypn1anddenovopt12n1breastcancer AT zeleidai prognosticdifferencesandtheeffectofpostmastectomyradiotherapybetweenpostchemotherapyypt12ypn1anddenovopt12n1breastcancer AT ningyuexu prognosticdifferencesandtheeffectofpostmastectomyradiotherapybetweenpostchemotherapyypt12ypn1anddenovopt12n1breastcancer AT tingluo prognosticdifferencesandtheeffectofpostmastectomyradiotherapybetweenpostchemotherapyypt12ypn1anddenovopt12n1breastcancer AT leiliu prognosticdifferencesandtheeffectofpostmastectomyradiotherapybetweenpostchemotherapyypt12ypn1anddenovopt12n1breastcancer |